Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Chung, Mar"'
Autor:
Hsing‐I Tseng, Yi‐Siang Zeng, Ying‐Chung Jimmy Lin, Jui‐Wen Huang, Chih‐Lung Lin, Meng‐Hsuan Lee, Fan‐Wei Yang, Te‐Ping Fang, Ai‐Chung Mar, Jung‐Chen Su
Publikováno v:
Molecular Oncology, Vol 16, Iss 11, Pp 2274-2294 (2022)
Hepatocellular carcinoma (HCC) is characterized by rapid growth, early vascular invasion, and high metastasis. Currently available US Food and Drug Administration (FDA)‐approved drugs show low therapeutic efficacy, limiting HCC treatment to chemoth
Externí odkaz:
https://doaj.org/article/cd433a0662f84954a5dfbfb4086997c1
Autor:
Tseng, Hsing-I., Yi-Siang Zeng, Ying-Chung Jimmy Lin, Jui-Wen Huang, Chih-Lung Lin, Meng-Hsuan Lee, Fan-Wei Yang, Te-Ping Fang, Ai-Chung Mar, Jung-Chen Su
Publikováno v:
Molecular Oncology; Jun2022, Vol. 16 Issue 11, p2274-2294, 21p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Te-Chang Lee, Hsiu-Hua Wang, Kuo-Chu Lai, Chi-Wei Chen, Tsung-Jen Lin, Chung Ji Liu, Zi-Xuan Hong, Ai-Chung Mar
Publikováno v:
Cancer Letters. 370:207-215
Our previous study demonstrated that the depletion of interferon-induced protein with tetratricopeptide repeats 2 (IFIT2) promoted metastasis and was associated with a poor prognosis in patients with oral squamous cell carcinoma (OSCC). Our current s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c20b75865b3915b2da708b3b98db39b
https://doi.org/10.1016/j.canlet.2015.10.016
https://doi.org/10.1016/j.canlet.2015.10.016
Autor:
Jeng Kai Jiang, Te-Chang Lee, Ai-Chung Mar, Shung Haur Yang, Hui Ju Lee, Jing Jy Cheng, Chun Ho Chu, Chia Wen Chien
Publikováno v:
Journal of Biological Chemistry. 290:22212-22224
Interleukin-1 receptor type 2 (IL1R2) acts as a decoy receptor of exogenous IL-1; however, its intracellular activity is poorly understood. We previously demonstrated that IL1R2 intracellularly activates the expression of several proinflammatory cyto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95b94b7f32f10fff43fcf156abd3c084
https://doi.org/10.1074/jbc.m115.644823
https://doi.org/10.1074/jbc.m115.644823
Autor:
Yeong-Shiau Pu, Meei Maan Wu, Hsiu Hua Wang, Te-Chang Lee, Ching Fei Li, Chien-Jen Chen, Ai-Chung Mar, Li Fang Lin, Alexander Sheng-Shin Wang
Publikováno v:
Oncotarget
// Meei-Maan Wu 1 , Ching-Fei Li 2 , Li-Fang Lin 2 , Alexander Sheng-Shin Wang 3 , Yeong-Shiau Pu 3 , Hsiu-Hua Wang 2 , Ai-Chung Mar 2 , Chien-Jen Chen 4 , Te-Chang Lee 2 1 Department of Public Health, School of Medicine, College of Medicine, Taipei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f1c49aa06afd50e8938bd6b467c43f1
https://pubmed.ncbi.nlm.nih.gov/28423602
https://pubmed.ncbi.nlm.nih.gov/28423602
Autor:
Hao-Chieh Chiu, Pei-Yi Chu, Te-Chang Lee, Jung Chen Su, Chung Wai Shiau, Ling Ming Tseng, Kuen-Feng Chen, Chia Yun Wu, Wei Tien Tai, Szu Hsien Wu, Chunyu Liu, Ai-Chung Mar
Publikováno v:
Scientific Reports
Patients with triple-negative breast cancer (TNBC) had an increased likelihood of distant recurrence and death, as compared with those with non-TNBC subtype. Regorafenib is a multi-receptor tyrosine kinase (RTK) inhibitor targeting oncogenesis and ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa5ce957f5765bbf9a0edfd83176f99
https://doi.org/10.1038/srep28888
https://doi.org/10.1038/srep28888
Publikováno v:
Cancer Research. 77:83-83
We have previously demonstrated that the expression of interleukin-1 receptor type II (IL1R2) is closely associated with the advanced staging and distant metastasis in patients with CRC. We also found that enhanced expression of IL1R2 played certain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c77950b88fb473aa8383fcc3ab6f1de7
https://doi.org/10.1158/1538-7445.am2017-83
https://doi.org/10.1158/1538-7445.am2017-83
Publikováno v:
Cancer Research. 76:313-313
Regorafenib, a newly approved multi-kinase inhibitor by US FDA, has recently demonstrated overall survival benefits in late-stage colorectal cancer (CRC) patients. We have preliminarily observed that the expression type II interleukin 1 receptor (IL1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87ab6816a17f78625ca96d5419e3467e
https://doi.org/10.1158/1538-7445.am2016-313
https://doi.org/10.1158/1538-7445.am2016-313
Publikováno v:
Molecular Cancer Therapeutics. 14:B54-B54
Regorafenib, a newly approved multi-kinase inhibitor by US FDA, has recently demonstrated overall survival benefits in late-stage colorectal cancer (CRC) patients. We have observed that the expression type II interleukin 1 receptor (IL1R2), an IL-1 d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a8346b16916bf48522d25597f48f87a
https://doi.org/10.1158/1535-7163.targ-15-b54
https://doi.org/10.1158/1535-7163.targ-15-b54